Citizens Jmp Issues Positive Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price

Cytokinetics (NASDAQ:CYTK) had its target price lifted by Citizens Jmp from $78.00 to $88.00 in a research note published on Monday,Benzinga reports. Citizens Jmp currently has a market outperform rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also commented on CYTK. HC Wainwright boosted their target price on shares of Cytokinetics from $120.00 to $136.00 and gave the stock a “buy” rating in a research report on Monday. The Goldman Sachs Group set a $95.00 price objective on shares of Cytokinetics and gave the company a “buy” rating in a research note on Thursday. Barclays boosted their price objective on shares of Cytokinetics from $82.00 to $87.00 and gave the stock an “overweight” rating in a report on Monday. UBS Group reaffirmed a “neutral” rating and issued a $61.00 target price on shares of Cytokinetics in a report on Monday, December 1st. Finally, Bank of America boosted their price target on Cytokinetics from $52.00 to $56.00 and gave the stock a “neutral” rating in a research note on Thursday, October 2nd. Fifteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $83.61.

Cytokinetics Trading Up 4.6%

NASDAQ CYTK opened at $65.60 on Monday. The stock has a market capitalization of $8.02 billion, a price-to-earnings ratio of -10.43 and a beta of 0.58. The business’s 50 day moving average is $62.83 and its two-hundred day moving average is $48.88. Cytokinetics has a 12-month low of $29.31 and a 12-month high of $70.98.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.59) by $0.05. The business had revenue of $1.94 million during the quarter, compared to analysts’ expectations of $6.05 million. During the same quarter last year, the firm earned ($1.36) earnings per share. The firm’s quarterly revenue was up 318.1% compared to the same quarter last year. Equities analysts forecast that Cytokinetics will post -5.24 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Fady Ibraham Malik sold 2,200 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $61.24, for a total value of $134,728.00. Following the sale, the executive vice president directly owned 138,552 shares in the company, valued at $8,484,924.48. This represents a 1.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert Arthur Harrington sold 2,150 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $66.80, for a total transaction of $143,620.00. Following the transaction, the director directly owned 18,542 shares of the company’s stock, valued at approximately $1,238,605.60. This trade represents a 10.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 148,494 shares of company stock valued at $9,488,218. 3.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Cytokinetics

A number of institutional investors have recently made changes to their positions in CYTK. UMB Bank n.a. boosted its stake in shares of Cytokinetics by 10.6% during the third quarter. UMB Bank n.a. now owns 1,762 shares of the biopharmaceutical company’s stock valued at $97,000 after acquiring an additional 169 shares during the last quarter. CIBC Private Wealth Group LLC raised its stake in Cytokinetics by 8.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 3,484 shares of the biopharmaceutical company’s stock valued at $191,000 after purchasing an additional 261 shares during the last quarter. Fifth Third Bancorp lifted its holdings in Cytokinetics by 32.3% in the 3rd quarter. Fifth Third Bancorp now owns 1,072 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 262 shares in the last quarter. Teacher Retirement System of Texas boosted its stake in shares of Cytokinetics by 1.1% during the 2nd quarter. Teacher Retirement System of Texas now owns 30,514 shares of the biopharmaceutical company’s stock worth $1,008,000 after purchasing an additional 341 shares during the last quarter. Finally, KLP Kapitalforvaltning AS grew its holdings in shares of Cytokinetics by 1.7% during the second quarter. KLP Kapitalforvaltning AS now owns 24,000 shares of the biopharmaceutical company’s stock worth $793,000 after buying an additional 400 shares in the last quarter.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: FDA approval of Myqorzo turns Cytokinetics into a commercial-stage biotech with a clear cardiology franchise and a long-term growth runway. This is the primary catalyst lifting the stock. Cytokinetics Wins FDA Nod For Heart Drug Myqorzo Zacks: Cytokinetics Wins FDA Approval
• Positive Sentiment: Analysts are raising price targets across the board (Barclays, Morgan Stanley, Needham, Citizens JMP, BofA), reflecting higher revenue and commercial assumptions post-approval — this supports additional buying and sets higher valuation anchors. Links to representative reports: Barclays, Morgan Stanley, BofA. Barclays raises PT to $87 Morgan Stanley raises PT to $71 BofA raises PT to $64
• Positive Sentiment: Product label differences give Myqorzo practical commercial advantages versus the incumbent (Camzyos) — notably flexible dosing that may ease prescribing and titration, supporting adoption and patient preference goals. Seeking Alpha: Small Label Differences With Big Commercial Stakes
• Positive Sentiment: Unusual options flow: a big spike in call buying signals increased speculative and/or institutional bullish interest that can amplify short-term upside and liquidity. (Internal trading item)
• Neutral Sentiment: Company-management commentary and the full conference-transcript provide color on commercialization plans and launch cadence; useful for modeling uptake but not immediately price-moving beyond the approval itself. Seeking Alpha: MYQORZO approval transcript
• Negative Sentiment: Management expects gradual adoption (targeting mid‑high 20% category penetration by end‑2026) and anticipates reliance on patient-assistance programs — this implies a ramp that may be slower than some investors hope and could pressure near-term revenue/margin visibility. Seeking Alpha: Small Label Differences With Big Commercial Stakes

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.